A review on preclinical studies conducted with Homeopathic medicine Cephalandra indica as an Anti-hyperglycemic agent





Cephalandra Indica, Diabetes Mellitus, Homeopathy, Preclinical studies, SABEH.


Background – Diabetes Mellitus a metabolic disorder affects the secretion of insulin from pancreas leading to hyperglycemia, if uncontrolled leads to complications triggered by free radical formed after oxidative stress. Homeopathic medicine Cephalandra Indica has shown antidiabetic activity in various potencies performed on preclinical studies on diabetic rat model. The present review highlights the pharmacological profile of homeopathic preparations Cephalandra Indica on preclinical studies and calculating the probable human equivalent dosage from preclinical studies for the pilot studies. Method – Articles published between January 1988 and December 2018 was included in review. Databases like PubMed – Medline, Google scholar were used for collecting the articles. Keywords like ‘Homeopathy’ or ‘Homoeopathy’, ‘Invitro’, ‘Invivo’ and ‘Cephalandra Indica’ were used. SABEH criteria were implemented for assessing methodology quality of articles. Results – Seven full text articles were included in review which had six Invivo studies and one Invitro study. This review article provided the scientific validation of high diluted homeopathic medicines pharmacological activity of Cephalandra Indica and probable mechanism of action confirmed through preclinical studies. Conversion of dosage from animal model to human dosage for pilot studies has been hypothetically proposed. Conclusion – Homeopathic medicine Cephalandra Indica has a therapeutic and safety profile with no toxicity observed in preclinical studies. The proposed hypothesis of conversion of dosage needs to be validated for further studies.






Theoretical and Historical Research